Greg is well known to THCB readers as a long term commentator on the oncology scene with a keen interest in chemotherapy assay testing. Here he writes about a new type of clinical trial — Matthew Holt
The traditional meaning of Health 2.0, according to Jane Sarasohn-Kahn’s "Wisdom of Patients" has been the use of social software and light-weight tools to promote collaboration between patients, their caregivers, medical professionals and other stakeholders in health.
An example of this in cancer medicine is Individualized Online Clinical Trial Protocol Version 1.0 by the Weisenthal Cancer Group, a Phase II evaluation of individualized cancer treatment with traditional cytotoxic chemotherapy, targeted anti-kinase drugs and anti-angiogenic agents.
With most clinical trials, investigators never give out information as to how people are doing. Most trials are failures with respect to actually improving things. The world doesn’t find out what happen until after a hundred or 500 or 2,000 patients are treated and then only 24 hours before the New England Journal of Medicine publication date.
Individualized Online Clinical Trial Protocol Version 1.0 is a
totally transparent clinical trial. Every patient who decides to enter
a study should know what happened to previous patients. Patients are treated in
real time, on the Internet, with the whole world watching to see how
they do. It includes weekly progress reports, and if individual patients
want, their own blogs as to how they are doing.
Stages have been implemented for a rather innovative clinical trial
with cell culture assays, "real time" on the Internet. The purpose of
the study is to show that cell culture assay technologies for
"targeted" agents really do work. The short-term future of cancer
therapeutics is combinations of "targeted" agents.